A strong expression of SSTR-2 (Krenning Scale 3–4 as fulfilled in the NETTER-1 trial) seems to have an impact on the outcome, but also site of the primary tumor, tumor load, grading and the Positron Emission Tomography (PET) with 68Ga-DOTA-peptide and/or with 18F-fluorodeoxyglucose (18F-FDG) uptake may influence the efficacy of PRRT. Here, SSTR2 is linked to neoplasm.